Apolipoprotein A-I
"Apolipoprotein A-I" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The most abundant protein component of HIGH DENSITY LIPOPROTEINS or HDL. This protein serves as an acceptor for CHOLESTEROL released from cells thus promoting efflux of cholesterol to HDL then to the LIVER for excretion from the body (reverse cholesterol transport). It also acts as a cofactor for LECITHIN CHOLESTEROL ACYLTRANSFERASE that forms CHOLESTEROL ESTERS on the HDL particles. Mutations of this gene APOA1 cause HDL deficiency, such as in FAMILIAL ALPHA LIPOPROTEIN DEFICIENCY DISEASE and in some patients with TANGIER DISEASE.
Descriptor ID |
D016632
|
MeSH Number(s) |
D10.532.091.200.100 D12.776.070.400.200.100 D12.776.521.120.200.100
|
Concept/Terms |
Apolipoprotein A-I- Apolipoprotein A-I
- Apolipoprotein A I
- Apo A-I
- Apo A1
- Apolipoprotein AI
- ApoA-1
- ApoA-I
- Apolipoprotein A-1
- Apolipoprotein A 1
- Apolipoprotein A1
- Apo A-1
- Apo AI
Pro-Apolipoprotein A-I- Pro-Apolipoprotein A-I
- Pro Apolipoprotein A I
- Pro-Apo A-I
- Pro Apo A I
- Proapolipoprotein AI
- Apolipoprotein AI Propeptide
|
Below are MeSH descriptors whose meaning is more general than "Apolipoprotein A-I".
Below are MeSH descriptors whose meaning is more specific than "Apolipoprotein A-I".
This graph shows the total number of publications written about "Apolipoprotein A-I" by people in this website by year, and whether "Apolipoprotein A-I" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
Year | Major Topic | Minor Topic | Total |
---|
1995 | 1 | 0 | 1 | 1997 | 1 | 0 | 1 | 1999 | 0 | 1 | 1 | 2004 | 0 | 1 | 1 | 2006 | 0 | 1 | 1 | 2007 | 1 | 0 | 1 | 2008 | 0 | 1 | 1 | 2009 | 0 | 2 | 2 | 2012 | 2 | 0 | 2 | 2014 | 0 | 1 | 1 | 2016 | 1 | 0 | 1 | 2018 | 3 | 1 | 4 | 2022 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Apolipoprotein A-I" by people in Profiles.
-
Jones WL, Ramos CR, Banerjee A, Moore EE, Hansen KC, Coleman JR, Kelher M, Neeves KB, Silliman CC, Di Paola J, Branchford B. Apolipoprotein A-I, elevated in trauma patients, inhibits platelet activation and decreases clot strength. Platelets. 2022 Nov 17; 33(8):1119-1131.
-
Nicholls SJ, Andrews J, Kastelein JJP, Merkely B, Nissen SE, Ray KK, Schwartz GG, Worthley SG, Keyserling C, Dasseux JL, Griffith L, Kim SW, Janssan A, Di Giovanni G, Pisaniello AD, Scherer DJ, Psaltis PJ, Butters J. Effect of Serial Infusions of CER-001, a Pre-? High-Density Lipoprotein Mimetic, on Coronary Atherosclerosis in Patients Following Acute Coronary Syndromes in the CER-001 Atherosclerosis Regression Acute Coronary Syndrome Trial: A Randomized Clinical Trial. JAMA Cardiol. 2018 09 01; 3(9):815-822.
-
Choi SH, Wallace AM, Schneider DA, Burg E, Kim J, Alekseeva E, Ubags ND, Cool CD, Fang L, Suratt BT, Miller YI. AIBP augments cholesterol efflux from alveolar macrophages to surfactant and reduces acute lung inflammation. JCI Insight. 2018 08 23; 3(16).
-
Damen MSMA, Dos Santos JC, Hermsen R, Adam van der Vliet J, Netea MG, Riksen NP, Dinarello CA, Joosten LAB, Heinhuis B. Interleukin-32 upregulates the expression of ABCA1 and ABCG1 resulting in reduced intracellular lipid concentrations in primary human hepatocytes. Atherosclerosis. 2018 04; 271:193-202.
-
Wang Q, Guo L, Strawser CJ, Hauser LA, Hwang WT, Snyder NW, Lynch DR, Mesaros C, Blair IA. Low apolipoprotein A-I levels in Friedreich's ataxia and in frataxin-deficient cells: Implications for therapy. PLoS One. 2018; 13(2):e0192779.
-
Sniderman AD, Islam S, McQueen M, Pencina M, Furberg CD, Thanassoulis G, Yusuf S. Age and Cardiovascular Risk Attributable to Apolipoprotein B, Low-Density Lipoprotein Cholesterol or Non-High-Density Lipoprotein Cholesterol. J Am Heart Assoc. 2016 10 13; 5(10).
-
Treuheit NA, Redhair M, Kwon H, McClary WD, Guttman M, Sumida JP, Atkins WM. Membrane Interactions, Ligand-Dependent Dynamics, and Stability of Cytochrome P4503A4 in Lipid Nanodiscs. Biochemistry. 2016 Feb 23; 55(7):1058-69.
-
Byers T, Goff D. Response. J Natl Cancer Inst. 2015 Oct; 107(10).
-
Byers T, Goff D. Breast cancer, heart disease, and whispering "fire" in a public theater. J Natl Cancer Inst. 2015 May; 107(5).
-
Taylor JK, Plaisance EP, Mahurin AJ, Mestek ML, Moncada-Jimenez J, Grandjean PW. Paraoxonase responses to exercise and niacin therapy in men with metabolic syndrome. Redox Rep. 2015 Jan; 20(1):42-8.
|
People People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|